Evicore Breast Imaging Guidelines

CLINICAL GUIDELINES Breast Imaging Guidelines Version 1.0 Effective February 1, 2021

eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies:This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or individual’s Primary Care Physician (PCP) may provide additional insight.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2020 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

Breast Imaging Guidelines Abbreviations for Breast Guidelines 3 BR-Preface1: General Considerations 5 BR-1: Breast Ultrasound 8 BR-2: MRI Breast 10 BR-3: Breast Reconstruction 12 BR-4: MRI Breast is NOT Indicated 13 BR-5: MRI Breast Indications 14 BR-6: Nipple Discharge/Galactorrhea 18 BR-7: Breast Pain (Mastodynia) 19 BR-8: Alternative Breast Imaging Approaches 20 BR-9: Suspected Breast Cancer in Males 21 BR-10: Evaluation in Pregnant or Lactating Women 22

______©2020 eviCore healthcare. All Rights Reserved. Page 2 of 26 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com 0 ukatrPaeBuead lftn C290(0)918- 29910 (800) SC Bluffton, Place Boulevard, 400 Buckwalter ______Breast ©2020 BI GERD COPD HRCT LFTP DCIS MRA LCIS EMG MRV AVM PEM ECG CAD AAA - NCV FDG ACE CTA CTV PET PFT MRI IPF RADS BP PE CT

GI Imaging l Rights All eviCore healthcare.

Guidelines electromyogram pulmonary positron positron pulmonary nerve magnetic magnetic magnetic localized lobular idiopathic high gastrointestinal gastroesophageal fluorodeoxyglucose electrocardiogram ductal computed computed computed chronic computer blood Breast arteriovenous angiotensin abdominal Abbreviations

resolution

pressure conduction

carcinoma

Imaging

carcinoma obstructive - emission

emission

fibrous -

resonance resonance resonance

pulmonary aided

tomography tomography tomography aortic function embolus - converting

malformation

computed

Reporting

detection

tumor

aneurysm

velocity

tomography mammography in reflux

Reserved.

pulmonary

tests situ

situ venography imaging angiography fibrosis

venography angiography of enzyme

disease

the tomography for and

pleura

disease Database

Breast

System 8924 BRCA CBC FDA FNA DVT

EM Guidelines

deep Complete tumor fine Administration Food electromagnetic

needle

venous

and suppressor

Drug blood

aspiration www.eviCore.com

thrombosis

count Page 3of26

gene

V1.0

Imaging l Rights All eviCore healthcare.

Guidelines superior solitary Rotating purified

pulmonary protein

vena

Delivery

cava

derivative

nodule Reserved.

Excitation

tuberculin

Off - resonance

8924

MRI www.eviCore.com Page 4of26 V1.0

Breast Imaging Breast Imaging Guidelines V1.0

BR-Preface1: General Considerations BR-Preface1.0: General Guidelines 6 BR-Preface1.1: BI-RADS™ Categories Chart 6 BR-Preface1.2: BI-RADS™ Breast Density Categories 7

______©2020 eviCore healthcare. All Rights Reserved. Page 5 of 26 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com  0 ukatrPaeBuead lftn C290(0)918- 29910 (800) SC Bluffton, Place Boulevard, 400 Buckwalter ______BR-  BR- Breast ©2020 Category 1: Negative Category 0: Incomplete Category Suggested Follow Interval – Finding Benign 3: Probably Category 2: BenignCategory Finding Current clinical evaluation is not required prior to screening studies. advanced imaging. A current clinical evaluation (within 60 days) is usually required prior to considering Preface1.1 .0 Preface1

Imaging l Rights All eviCore healthcare.    A clinical evaluation should include the following:

Category established patientcan substitute a face for- Other meaningful contact (telephone call, electronic mail or messaging) by an mammogram and/orultrasound Appropriate laboratory studies and non- A r elevant history and physical examination Guidelines - up Short : : :

BI General

- RADS

BI study be specified, e.g.study bespecified, ultrasound, additional mammogram 0classification Category additional imagingthat requires mammographic evidencemammographic of ma fat calcifications, e secretory multipl fibroadenomas, describewish a to calcified finding. Involuting, isThis also a negative mammogram, but the interpreter may are calcifications suspicious andnosymmetrical or masses, architectural disturbances, is nothingThere commentto on. breasts areThe MRIview, comparison Need additional imaging evaluation prior mammograms or for findings that should that findings be interval follow available becoming on light sheds that the would radiologist the is notIt expected to change over the follow beingprobability benign. of A placed in categoryfinding should havethis avery high vali as the to accrue data will These undergointuitive. modification as future likely more implants, etc.nodes, while concluding still that is nothere might wishinterpreter intramammary to describe lymph andappearances, may be labeled with The confidence. and mixed density all hamartomas) have characteristic lesions (such containing oilas cysts, lipomas, galactoc - Reserved. RADS™

Guidelines ™ dity of an approach,dity and of the interval required, the type of

Categories .

- up. At At up. the time,present most approaches are

advanced imaging modaliti prefer establishprefer Data itsto stability. is

followed.

Description

Chart 8924 Chart

- present. face clinical evaluation

lignancy.

efficacy short of - up interval, but up interval, but www.eviCore.com es,such as Page 6of26 - eles, V1.0

Breast Imaging Category D: ExtremelyCategory dense C: Category B: ScatteredCategory densit fibroglandular A: AlmostCategory entire fatty 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______BR- Breast ©2020 Be Taken Action Should Appropriate Malignancy –Proven 6: KnownCategory Biopsy Be Taken Action Should Appropriate of– Malignancy Suggestive Category Be ConsideredShould Abnormality 4: SuspiciousCategory Preface1.2

Imaging eviCore healthcare Rights . All

Categories

. .

www.eviCore.com

Page 7of26 V1.0

Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______     Breast     ©2020 necessary Ultrasound US Axilla any nipple especially limited) Breast Routine biopsy Palpable scre State Specific Density Reporting and Imaging Mandate Laws usefulness. automated 3D nonspecific, BI

- Imaging eviCore healthcare Rights . All RADS

 Equivocal U Breast Bilateral For individuals If months If A  ultrasound abnormality not density should nodes Reconstruction

guided Additional order, ening

ltrasound repeat repeat

clinical ultr

inversion) See CPT Radiologist MRI ultrasound to indicated

women

can performance

asound ™ breast . document Guidelines

mammography density in

be assessed

regardless

for

breast notification ® breast Breast from CH- Breast

Cat should be

imaging imaging equivocal 76642) offi differentiating

breast

risk lesions with

screeni

with used 2.2: Axillary2.2: Lymphadenopathy 3 has

Occul ce

. masses

the 1,2,3 should (CPT

biopsy ultrasound ultrasound

not (CPT Report a a

profile. can

visit (CPT

be successful successful

c been

date and

is rem to BR-1: linically ultrasound. FNA

ification

of of

t t ng s

® B coded laws

be further hould is Findings: ®

as 76882)

breast

be ® age.

I-R

ains

inconclusive

76641: (CPT for of uncertain.

identified not recommendation is repeated 76376 or

cysts

benign

othe evaluated ADS

vary, the

Reserved.

inappropriate. women BI-R

biopsy

suspicious follow CPT (ABUS); necessary be Ultrasound laws

® evaluate Breast

ultrasound lesion

initial r

19083) ™ 1 1 ™

billed unilateral, from It or clinical but ® ADS

(Cat is have

on can can 76882x 2. at up CPT

whose

or commonly some

imaging.

with

sampling solid least there recent using ™

imaging

2).

2, abnormalities

includes lymph ® help prior been conflicting abnormalities can

16 76377) then 1,2,3 as Ultrasound

mammography

6 complete also lesions for

only

repeat is CPT

identify enhance stand- (within months to

put

After Breast nodes, imaging

for

requested contain breast

indication

the

histology in the Chest Imaging Guidelines evidence is 8924 8924 into

stable 19084. 1 at findings

2 2 alone

not

the imaging

patients

after

found ultrasound years

(such effect preoperative

biopsy ultrasound

considered reverts mandates

last

months, CPT

findings

screening

and an is in is

on of

as dense

conjunction

. component. benign

® who support 3 US

stability,

breast mammography

76642: mammogram, skin to many days)

(CPT

18 directed

at routine

when have for

medically axillary

6 breast

or change, months, and

states. states.

www.eviCore.com

ultrasound, mammogram. additional its

months

® unilateral,

with

the

76641 positive

an clinical with Page 8of26 per

tissue breast

finding

Breast pain, and

or or

V1.0

is in

Imaging eviCore healthcare Rights . All i involving maging, Guidelines

which members

may

include

these Reserved. states, MRI

and/or

their

ultrasound. legislative 8924 8924

mandates

For

applicable

should www.eviCore.com requests

be Page 9of26 followed.

V1.0

Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______      Breast   ©2020 pharmacokinetic analysis), when performed; bilateral CPT document MRI MRI the use of (CPT 77047) or M preferred Magnetic most computer Magnetic resonance imaging, breast, without and with contrast material(s), including pharmacokinetic algorithm The The equivocal unnecessary integrity Magnetic resonance imaging, breast, without contrast material; bilateral (CPT pharmacokinetic computer Computer

Imaging eviCore healthcare Rights . All Additional HCPCS CPT Since The The with MRI interpretation. investigational,

® use use Breast guided ® individuals 77048

7704

® use use further

in of of

- 76377 -

reast the Guidelines resonance in successful successful analysis - or aided detection (CAD real aided

gadolinium contrast.

aided asymptomatic,

gadolinium gadolinium

code can 6) 6)

agnetic resonance imaging, breast, without contrast material; unilateral breast of of some

uncertain.

procedures.

with CAD lesion H

maybe performed CAD

physician data

be CPCS detection should

for detection analysis, analysis), 9

C8937.

these

individuals

s experimental, biopsy repeated s oftware the has for

imaging, MRI should lesion

5 contrast contrast

c lesion not

evaluation procedures. ode lit

review B

The

tle average- (CAD (CPT with

(CAD)

BR-2: when

be reast automatically Reserved.

sampling

C8937 be

at influence use after breast, detection/characterization,

used

further least ® is is

billed real for

19085) data and/or

performed; is if there are clinical reasons or concerns regarding not required

of mas of risk

interpretation) included - -

in (CAD 6 6

time lesion detection, characterization and time HCPCS

MRI

breast

necessary physician physician without

if using

for conjunction

months on tectomy

patients. u histology

includes

lesion nproven.

lesion performs the including for

Breast CPT parenchyma.

with unilateral

code and sensitivity the a , ,

fter detection/characterization, per detection, review for ®

the

the evaluation 8924 8924 with 19086. is

with

C8937

3D benign computer the

an physician currently

MRI (CPT imaging

contrast (CPT

imaging,

MRI CPT

for evaluation specificityand

pharmacokinetic B

(CAD ® characterization interpretation) and

reast ® directed ® 77049 of

77049,

77048 considered algorithm component. request.

breast material(s), nonspecific,

CPT including

CPT ) of ) is

breast ®

CPT implant may www.eviCore.com

® 76376 preferred parenchyma. of

77049 analysis Page 10of26

is MRI

computer be analysis,

77048 including and biopsy or ®

B and

reast in

V1.0 of

Imaging eviCore healthcare Rights . All Notes . 6,7 with MRI by Guidelines

varies

MRI

younger and Breast it

carries

from Breast

ultrasound.

has

3% age a a

significant

superior to . .

only The

Reserved. 20%

Incidental

0.7% percentage

depending

sensitivity

false

those lesions

positive of

in on

with inci

identifying

are the 8924 8924 risk dental

“inconclusive

patient seen

when

lesions

on new

population. compared

15%

unknown

that mammographic

MRI

turn www.eviCore.com

to Cancer Page 11of26 B

out reast

be V1.0 and

Imaging eviCore healthcare Rights . All Deep Inferior Epigastric Perforators (DIEP) flap. For example, CTA 74174) be

performed MRA

currently Guidelines

imaging or MRA Abdomen MRA or and/or

the

BR-3: insufficient

for

body

breast TRAM A bdomen bdomen

part

Breast reconstruction Reserved.

flaps evidence- from and

or which

/or

Pelvis Pelvis

other

Reconstruction P based

elvis the

flaps (CPT preoperative

free data (CPT

performed ® tissue

8924 8924 74185 and

to 8 ®

74175CPT or support transfer planning. on a /or

the

CPT flap vascular

need 2,3 ®

is ®. www.eviCore.com 72191CPT or 72198) for

being for Page 12of26

pedicle

routine

taken, V1.0 . 8 ®

Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______     Breast  ©2020 Routine surveillance MRI Breast following bilateral investigational, Surveillance Low Patie MRI coverage and/or Suspicious or guidance

Imaging indeterminate eviCore healthcare Rights . All policy. Their coverage policies will take precedence over eviCore guidelines. surveillance MRI in these patients would also not be included in the coverage  risk date,To ev breast Certain payers donot include breast implants in their coverage policies if the A lesion categorized as have BI Repeat (  risk, Radiologist Report)inBR-5

Breast nts

If individuals If 18 stability, mortality. factor

repeat repeat with probably implants were placed as part of purely cosmetic surgery. Thus, Guidelines or policies months

the (BI

should physical

MRI BR-4: dense is

- i

ori

dence RADS™ the as imaging imaging breast

However, lesion(s)

, , take ginal for risk

and there

benign not finding breasts

silent/asymptomatic exam, does nots

profile.

MRI be precedence density type 24

4 4 is remains is

BI-

that used months (BI or

no should certain

such such

study Reserved. as

RADS evidence RADS™

Breast can

[Se

determined lesion to : BI-R uggest MRIBreastIndications].

(mammogram, assessedbe e heading“EquivocalorOccultFindings” determine from

payers

be - over ™ 1 1 ™ RADS

palpable masses

ADS readily on

3) i the basis

mproved outcomes for w eviCore or

mammogram rupture is lesions may ™ ™ 3,

2, date by

biopsy 4 or

biopsied, NOT that

then

mammogram cover as repeat

5should be biopsied. guidelines.

US, of

surveillance 8924 8924

benign imaging the mastectomy is not indicated.

silicone recommendations

this

Indicated or

and

initial

original either and/or

MRI) surveillance

(Cat

microcalcifications

13,14,15 reverts

17,18 implants imaging

using

ultrasound reduces study 2). 6

w omen 16

months

imaging

. .

is www.eviCore.com routine After and

for 16 12 morbidity considered Page 13of26

hose only suspicious

those months 2 2 years per . 3,6 45

V1.0 , ,

Imaging eviCore healthcare Rights . All with M Evaluate breasts, mammography Evaluate Assessment   in A Fat result Discordance Radiologist tissue diagnosis ofmalignantphyllodestumorhaspreviouslybeenestablishedby mastectomy. have close  a change observation. conflicting uninterpretable. ultrasound discrete

fter Breast Breast 6 6 BreastRI probably

D D If If May individuals 24 findings surgery finding reconstruction, Necrosis

months

physical iagnosed iagnosed the repeat repeat

does

Guidelines

months diagnosis. successful successful or or Tumor .

in 26,28 evaluate

is palpable can reconstructed R

discordant Occult Occult uncertain. clinic or

ecurrent surgical findings should

indicated

(BI i benign

or (lumpectomy

not Report of conf

imaging imaging s

29 be of between (mos examination

preoperatively indicated toestablish (Cystosarcoma

BR-5: positive - fat al risk from Breast Paget’s RADS

adequately resi and/or 1 repeated irm

Findings 18,19,20 suspicion with necrosis mass. be

lesion

profile. management lesion free

dual on

Malignancy R 5

commonly the

biopsy, breast

for assessed is remains ecommendation TM

Cancer MRI

mammography margins,

imaging BI-R ultrasound,

breasts, Disease (

4 4

date injection,

breast S tumor MRI

Reserved. sampling or ee PracticeNote) on

at or

in of if implant

mastectomy explain

ADS before

least a a

5). MRI of Ultrasound

other BI-R 4 recurrence,

Phyllodes)

due (including augmentation, woman findings

the

Breast 5 as and when MRI

™ 1 1 ™

(thereafter

29 patients 6 6 and

(MRI

ADS

benign

if if clinical consideration initial to rupture the months

possible those histology Breast

trauma capsular for the or

™ with abnormal BI

and 2,

or with ultrasound imaging.

DCIS) MRI

who following findings 3,

RADS (Cat

indicators.

then

evaluations Indications a a when

mammogram

after

can treat core repeat

chest

or or

history

Breast breast is

have 8924 8924

contracture 2). .

imaging

1,6,24,25,26 surgery) without be

TM benign

an mammography needle findings as for

16 After may

extent ofdisease where a

3) 3) evaluations

wall used at

surgical undergone MRI of DCIS

of implants and This

should 12 a a

are 2 indicate

breast

recurrences and

reconstruction) reverts

finding biopsy

directed inconclusive for

months, reports years on

according

applies inconclusive to:

further nonspecific, mammogram undergo

management

(saline cancer

a a

with lumpectomy of findings. to that

or inconclusive

significant

breast

18 to www.eviCore.com stability, routine

evaluation ultrasound

following

intact to months,

or Page 14of26 treated repeat

or not

these

silicone),

biopsy

Biopsy a

per

conflict and/or vs. the

and

MRI

V1.0

with

and

breast screening screening screening screening

Imaging eviCore healthcare Rights . All Clinical with A cancer One age One Two indicated relatives First additional The ATM, PTEN age BRCA Patients whichever starting Li BRCAPRO clinical patient

- first Fraumeni

cancer

- 25 50 following breast or first first degree

CHEK2, Guidelines

or Mutation .

of BARD1, Lobular Atypical Atypical risk unknown

has more

lifetime begins to to to for

) )

- - or with . second

degree degree )

with

intermediate

MRI begin begin begin

age comes

BRCA annual cancer estimator

been models

but

Syndrome relative first a

have

BRCA

NBN

screening at

history

carcinoma risk

lobular ductal (Cowden not MSH2, - at at at

relative relative -

significance, degree tested

age degree first or . 2

age diagnosis age .

unknown , MRI

prior estimated

begin

1 (parent, at

Peutz

such .

40,

hyperplasia

penetrance.

the or hyperplasia determined 20: (TP53 MLH1,

B and

male with with to

relatives is Syndrome

or BRCA

Reserved.

age reast

- in

as age

High Jehgers the not

negative

situ or sibling, but

bilateral breast

Gail, genetic

at relative M mutation)

age of indicated years insufficient

screening greater 2,

SH6, not (LCIS)

Risk

the with

(ADH) 41

Claus, if by

(ALH) of

), Syndrome

cancer

prior child patient

for earliest

before

CDH1, variants breast 25 (father, gene

PMS2,

breast Indications

should than

: mutation

to ,42,43 4,12,22,30

Tyrer

Half

evidence

this

or mutation

age has

the

cancer,

NF1, or diagnosed ee

EPCAM,

brother, or

ovarian favoring

(STK11

siblings -

start time:

equal Cuzick age ovarian not 25 table 8924 8924

then PALB2 :

been

: annual

of of or

to uncle

cancer

below: RAD51C, polymorphism, LKB1 breast annual relative are both (also

cancer breast 20%

tested begin

considered

breast

grandfather known

gene

that using

cancer

screening

when . cancer

age

for Genetic

was

screening variations)

and genetic BRCA as

30 first risk

genetic www.eviCore.com diagnosed in second

IBIS)

ovarian )

the diagnosed and variants diagnosed Page 15of26

. mutation

not risk

or family, MRI

begin

variants

degree

≤

of V1.0

(If

Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Practice Breast   ©2020 1 1 1 1 6 5 4 3 MRI State Specific Density Reporting and Imaging Mandate Laws sonographically Phyllodes . . . .

Imaging eviCore healthcare Rights . All phyllodes), If It Treatment Diagnosis fibroadenoma, Phyllodes density Breast biopsy). shown imaging, involving recommended. breast MRI tissue breast MRI breast breast MRI radiotherapy Annual exposure estimated such

should biopsy has Notes

Breast Breast Breast a a as

Guidelines

( Tumor cancer cancer. cancer cancer

densit to Breast DensityBreast Total Total Mini Axilla Mediastinal Whole Chest MRI notification

predilection

the FNA not

est

which members be

tumo is

it surveillance surveillance surveillance

Gail, mantle, the ablishes

Breast

greater body

(TLI) made (whichever of suspicious

y wide

should (thorax) (Cystosarcoma biopsy (not (not (not 11,12 lung

notification

although

value following r may used

Claus, is

or irradiation

treated treated treated

l is

Personal ocal usually by

laws mant in

than

subt

for

a a include

recommended is in

in Category

these tissue

diagnosis

inaccurate (annual) (annual) (annual) Tyrer occurs local

lieu

excision. treated distinguishing

otal le, fields findings or they vary,

Reserved. with with with

laws benign or equal

(TBI) of (SLTI) - Additional states,

MRI

diagnosis

Cuzick recurrence

H extended may bilateral bilateral bilateral

for

but Phyllodes) later) mammographically, D) istory

is is is as have

any

(ACR

and/or Axillary on

indicated indicated indicated

some a a

and exhibit in lymphoid beginning

20%

their for

or malignant

mammography soft pediatric

phyllodes

been mastectomy) mastectomy) mastectomy)

BRCAPRO fibroadenoma Practice

mantle patients has (percutaneous

using

also

ultrasound. following B legislative

tissue

lymph isks: rapid

reast

for for for put clinical irradiation

contai

cancer: genetic patients patients patients

phyllodes

receiving 8924 8924 age into sarcoma ( sarcoma

tumor growth.

Guidelines). node dissection C

models

diagnosed and who ancer local

characteristics clinically, 39 25 n n effect mandates

For

risk from

mandates

with with with diagnosis

or extremely core a had

excision. Breast therapeutic

(cystosarcoma (cystosarcoma

8 applicable or prior

See a a a years phyllodes

clinical

biop personal personal personal

before clinical many and/or

should

- ONC MRI

initial for dense after sy and

risk of

states. states.

www.eviCore.com

radiation or age not additional

lifetime requests has

12: history history history is tumor. completion

diagnosis

excisional be Page 16of26 estimator

breast

not necessary. 50

not followed. . 39

Breast risk

of of of

been

V1.0

Imaging eviCore healthcare Rights . All Guidelines Sarcomas– Guidelines ). 18,19,20 Bone,

Soft

Reserved. Tissue

and

GIST

the 8924 8924

Oncology

Imaging www.eviCore.com

Page 17of26 V1.0

Breast Imaging 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______ Practi     Breast ©2020 prolactinoma; For and and If unilateral, Mammogram Physiologic Pathologic determined commonly single colors hyperprolactinemia nipp

Imaging eviCore healthcare Rights . All ce If If

technically milky the mammogram mammogram the

Notes le duct, including

patient

discharge nipple

discharge, Guidelines

limited)

BR-6: - multi nipple

by nipple persistent,

and pituitary results. limited,

can di serous, duct. scharge

discharge

and should ultrasound

discharge is and

can be

Nipple prolactin physiologic,

31,32,33,34 MRI

imaging ultrasound

reassured. and

is be yellow, trasound

be is predominantly B

considered spontaneous.

Reserved.

is pathologic, reast obtained is (CPT

and defined

is predominantly green, Discharge/Galactorrhea

not there 31,32,33,34

are can TSH are ® 76641:

needed negative,

as (S be as negative, brown,

are levels ductography

milky,

ee initial unilateral, performed.

unilateral, Practice

suspicious suspicious are bilateral, or

imaging,

normal but no

and gray.

8924 8924 recommended

additio may

bloody

31,32,33,34 ductography should Note

complete Evaluation serum

but be with nal findings

). white may or 31,32

clinical

imaging

serous, serous, Prolactin.

attempted.

be or 33,34

to or

for is on

CPT

a unilateral. diagnose

pathway unavailable

www.eviCore.com clinical variety is arising

® necessary, Page 18of26 76642:

exam,

from It

is V1.0 or a

Imaging eviCore healthcare Rights . All If

® risk evaluation Notes 76642:

mammogram,

of evaluation Guidelines

imaging malignancy test, m

unilateral, and BR-7: is

ammogram ultrasound not

is (evaluation

ultrasound) NOT

negative,

following

limited) Breast

routinely Reserved.

are and . S includes 39 a a

has the ee

ultrasound negative

indicated

BR-5: Pain

initial been

patient imaging estimated MRI clinical

(Mastodynia) (CPT in

Breast patients history 8924 8924

® examination for 76641: to

breast

and

Indications

be with

only

physical unilateral,

breast pain.

(clinical 0.5%.

pain

exam, www.eviCore.com

39 complete breast Page 19of26 and

V1.0 or

Imaging eviCore healthcare Rights . All b CT Breast(CPT Other techniquestodetecto Impedance Thermography   Nuclear breasti     for There microwave transmission, PET   time CPT or 0637T,  Cone BeamCTBreast detection. I BR-8:

Breasts Molecularbreasti Scintimammography reast imaging modalities. and/or

Notes alternative this modality, and this procedure should be considered investigational at this showed that PEM and MRI hadcomparable breast mammography. The radiation exposure from a PEM study is 23 times higher than for digital levels. need for MRI hadgreater lesion women underwent both high- breastcancer ant A prospective multi modalities well as in detecting incidental breast cancers not seen on other imaging identified as suspicious onconventional imaging or physical examination, as Early clinical trials have shown high clinical accuracy in characterizing lesions technique is especially adept at detecting ductal carcinoma in situ. and allows visualization of intraductal as well as invasive breast cancers. This The spatial resolution of this technique is at the individual duct level (1.5 mm) breast The PEM high Systems, also referred to as Naviscan™ or PET mammography, performs High Requesting providers often ask for PEM as CPT mammogram. allowing

Mammography(PEM)

Guidelines is currently insufficient data available to generate appropriateness criteria - -

resolution positron- alternative

resolution ”.

Of Of these, 3.6% of the women had tumors seen only with PEM. Alternative

Mammography

with

imaging(BSGI) pecific gamma t remains under investigation, and is not to be used in lieu of conventional acquisition of the emission images immediately after mastectomy. PEM had greater specificity at the breast and lesion

detectors are integrated into a conventional mammography system,

breast ®

maging, including: 0638T) ® respect

0633T, ing and currently being studied as a mode of breast cancer metabolic imaging for breast cancer using anFDG tracer. breast

imaging i maging cipating breast - center clinical trial for women with newly diagnosed

to Reserved. nitrous CPT

- both imaging level sensitivity andmore accurately depicted the emission mammography (PEM) by Naviscan™ PET xygen (MBI) (MBI)

Breast techniques ® 0634T, CPT 0634T, screening oxideproduction resolutionPEM imagi

consumption,l

techniques - conservation surgerywas performed. These

Imaging may

and ®

0635T, CPT 0635T, have

8924 8924 diagnosis include: ight absorption, FDA ® 78811 or “PET scan of the

ng and breast MRI. Results - Approaches level sensitivity, although

approval, of ®

0636T, CPT 0636T,

breast

the

www.eviCore.com

cancer. they Page 20of26

remain ®

V1.0

Imaging eviCore healthcare Rights . All

men men

is cancer diagnostic BR-9:

tissue tissue

examination, limited <25 ≥ Guidelines 25 if

or mammography years years

in suspicious. as

diagnosis. evidence

men

Suspected initial

pathway

of of

presents age age mammography imaging on

with with

for

Reserved.

is the

inconclusive suspicious an an as

followed use a mass, a mass, indeterminate indeterminate

Breast

MRI

recommended by

clinical skin/nipple

or in mammography suspicious.

the

Cancer palpable mass palpable or

8924 8924 evaluation

imaging

change,

initially mass,

in if

findings

ultrasound

followed or

male or

Males ultrasound

pathologic

with

www.eviCore.com usually breast a a

by Page 21of26 concerning is

disease. nipple V1.0

Imaging eviCore healthcare Rights . All Gadolinium

US nipple Guidelines

is Evaluation

first

discharge (with

is after in

- required line

pregnancy.

lead

mammogram woman

imaging

abdominal and with

Reserved.

has US

Biopsy, in MRI

a is pregnant Pregnant and

palpable

negative

shielding). to

evaluate rather US.

and mass mass or

than suspicious, suspicious,

lactating breast

or OR advanced 8924 8924

Lactating has parenchyma,

women.

persistent follow imaging,

with

but

unilateral

www.eviCore.com is diagnostic Women

is Page 22of26 V1.0

Breast Imaging 11. CD, Lehman 10. .Dorrius 9. of College American 14. Mendelson 4. 8. 3 Emaus 13. 18. BL, Sprague 3. 7 McCarthy 17. 16. .National 5. 12. 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918- ______15. MB, Mainiero 2. 1. Reference Breast .Moy 7. .Peters 6. ©2020 Guidelines™) Cancer. Testing. NCCN 2013 detection systematic trial review ultra detection Reconstructive - Pinel 1134. Holmich screening findin rights MRI based Gynecologists. Oncology Thyroid br NCCN. the may herein complete for atlas, Ann https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/bre November Final Sickles - Dense - Publications/Committee by diagnosed ast Breast screening NCCN.org. Cancer Comprehensive Saslow Siu eas

- Imaging

any eviCore healthcare Rights . All cancer AL.

study

sonography Intern as L, ;

Recommendation t Giroux br reserved. – 200(6):W683

practice

lesions.

Guidelines of

G, NHG,

system data and reporting imaging

Breasts

Elias

purpose MJ, an ? EA

MD, D, for Screening

east Carcinoma. L

Referenced National Cancer Comprehensive

s s

surgical

Journal American

novice among of

of version . R, (NCCN

n. n. desig

CM, for

Boetes adjunct

Journal Med. 2016.

review

. screening D’Orsi and To EB,

Guidelines not Bakker V

breast

I, Vejborg reporting imaging K, FM,

Stout

Blume

Borel

rupture: A, Lourenco mammography an der

for

view

- Pusi

Radiology

to approach Obstet

Surgery in be reproduced Pate - Diagnosed Böhm

The

without 2016 screening

Breast C Comprehensive El

methods Guidelines™) Radiology

Version NK, NK,

of cancer Rinkes

c c

MF, nd

most the Khoury the JD,

Referenced l . W689

NCCN

with Obstetricians

MC Weide A, mammography Burke

V, the ; - breast

do U.S.

Vélez Gynecol CJ. - meta - 164(4):279 Conrad

: Schechter

Statement: NCCN Kerrigan and

Peeters the et DeMartini Network, breast experienced and - Opinions/Committee Cancer July

American permission ; 2008

ACR 2.2017. Mahoney al. IH for

e by and spectrum

W, of patient Guidelines™ MM,

analysis

M, cancer: 50 aged women

M, xpress . recent ; 1 ; 2004 2015

food Roentgenology . Mammography#here Opinion Committee with women C,

. and Guidelines, et

J, J,

Berg BI Breast 246(1). Zuithoff ; 2015

for PHM,

2.2017 with Trop any

Network

Reserved. al. Inc.

Ooijen van

et -

C, ; WB,

296. Gynecologists. and

Invasive

RADS

ca and system data Breast College

ancer Breast 277(2).

complete and

. written

al MC,

Cancer American 14 US from et from permission WA, form

CL.

CA re? Eur

All I, . . 125

MRI (1): et Untreated al. drug

Preventive

® National 2014 al. rights

Cancer et and

Plastic

Silicone of

. Network

al.

Radiol. NCCN the

(NCCN) et

Cancer: for al. Benefits - 204 Cancer Follow breastsdense go Reston,

https://www.acog.org/Resources A,

permission of Breast al.

helpful

findings imaging MR

recommendations administration al.

Accuracy

PM . medical Continuing

on- illustrations 75 any

to online Radiology et

; 1 ; 2009

ACR

214 reserved. .

ACR

& & as Imaging MRI J J al. College American Gynecologic A, years

August

purpose breast

Silicone

of version No.

Screening (NCCN)

, Guidelines Cancer: Reconstructive . Clin . . Screening

VA, et - Meta Services harms, Appropriateness

Clinical

and Outcome readers

evaluationthe

the

al.

93(4) 625

Management

Society and

with

of - NCCN.org ; 2007 of College American Cancer Comprehensive RADS .

implants

Computer . The ; 2011 analysis ; 2013 NCCN may herein NCCN. the

Ann Breast

American without

interpretation

Guidelines Principles : and cost 8924 8924 extremely an

- 986 .

the Practice . Task - d and

Radiographics 57(2) NCCN Practice/Management Version G ® Journal American

U.S.

Intern additional

– 21(8):1600 - 10(1):11 Ultrasound. NCCN uidelines . 993 Clinical

education:

. Implant

Diagnosis

magnetic and

of Surgery: the

Force - - :75 of Services Task Preventive Monitoring.

Aided -

of of

effectiveness College

Guidelines™

Criteria not

Med Guidelines

Radiology of

breasts dense

– – 2.2017 express 2.2017: Version with women mammographic inconclusive

89. Guidelines,

Breast Dedicated view

Practice

imaging 14. time statement. recommendation be r

screening

. Rupture, for in Detection

; ; 2015

April

1608.

- . ACR In: 2.2017. breast Radiology ®

And

eproduced of

2013

breast the

of reflect

Breast

written

In:

May . Obstetricians of of

Network,

resonance

computer 2008 -

in . 2013 most - 162(3):157 in Guidelines

; ACR

illustrations and of

www.eviCore.com

Roentgenology Plastic

Oncology breasts dense reconstruction: go 33(2):

modality the

screening : ©

17, BI an of

supplemental cancer The 2017 ;

of permission

. - to online Page 23of26 Breast - recent

(4 121 Breast

Women RADS diagnosis

BI - evidence 2013. in 2017.

435-

Inc. & - - DENSE

MRI aided RADS

an National imaging

in ): for

. 166

y (NCCN and Force and ® All MRI 453. - 1127

with

form -

Atlas, With V1.0 the ®

of : A : . -

Clinical (NCCN) NCCN 2012 Clinical NCCN (NCCN) recently for andsurveillance workup of RADS online Tan CD, Lehman NCCN Guidelines, written NCCN Institute Network NCCN Network NCCN p illustrations pathologic online of permission illustrations NCCN the Gu (NCCN) written written and and and NCCN Morris Guidelines, Moy National Lim National © © © Institute Radiology Grau 2014 2014 2014 ermission

the idelines, Imaging l Rights All eviCore healthcare.

HS illustrations illustrations illustrations H, L, ; AM

81(1) College American

® to

National National National

Z EA, Guidelines Guidelines Guidelines Clinical Clinical Guidelines Guidelines of permission of permission permission

Newell

Practice Practice

Atlas,

breast diagnosed

for

for Guidelines Guidelines Guidelines S, hang Cancer Comprehensive Cancer Comprehensive (NCCN) (NCCN) , NCCN.org. NCCN.org

Bapsi

al. correlation. Clinical

Comstock

2013. : of Guidelines Clinical Clinical go herein herein go go e62-

Gatsonis

Paget

NCCN. the NCCN. the

Breast

online Practice online Practice Comprehensive Comprehensive Comprehensive

nline herein herein herein

C, Guideli Guidelines . 69. S,

Liu Guidelines Guidelines

Version Version Version Version Version may may

Practice

Chugh . . Systems Improvement Systems Version Version Version of Disease

the the ahoney the Reporting Imaging to to CE,

Radiographics C,

may may may

nes et not not Guidelines Guidelines

NCCN.org NCCN.org. NCCN.org of

NCCN. NCCN. N

To To

Kuhl

R, al, Lee CH, cancer.

2.2017: 2.2017: 2.2017: 1.1017: CCN. 2.2017:

Radiology

be reproduced be reproduced n

Guidelines in in local not not 2.2017: 2.2017:

2.2017:

Version Version view view Improvement findings Imaging ot MC, et

Oncology Oncology

CK,

the

in be reproduced in be reproduced in be reproduced Cancer Cancer Cancer al.

To To T Network, Network, recurrence

Reserved. N most the most the et

. . . . Invasive Ductal Phyllodes Paget’s Breast et in in breast: Phyllodes et

view view view Breast Breast Breast

al. Engl

2.2017: 2.2017: . . Oncology Oncology al. al.

; 2011 ; ; 2016 in

ACR

Network, Network, Network

and (NCCN (NCCN ACR

MRI J J most the Oncology most the most the

in Carcinoma Cancer

in in mammographic,

(ICSI) Diagnosis (ICSI). Inc. Inc.

Disease. recent recent Cancer. Cancer. Cancer. . Med Breast

31(7) 13(11):43 and System. Data

Appropriateness any any Breast Breast Tumor

evaluation tumors

BI in

All All (NCCN (NCCN

- , Guidelines™) Guidelines™) phyllodes

;

RADS

distant form form 2007

any any any Inc. Inc. Inc.

; Jan. 2012 Risk

and rights and

recent recent recent

ights Cancer - 1973

(NCCN

Referenced Referenced Breast Cancer. Cancer. National National

form form form All All All

- for for complete complete ; March

Reduction

® 52.

Guidelines™) Guidelines™) breast. the

Situ.

reserved. reserved. metastases of

Magnetic rights rights rights 1987.

complete and complete and complete and any any

tumor for for for

National contralateral the Reston, Cancer. Guidelines™) US, 8924

45 p. of

Referenced Referenced National

Comprehensive Comprehensive

purpose purpose

criteria any any any

- 356(13):1295

for for breast reserved. reserved. reserved.

and of version of version with with s s

National Breast Breast

purpose purpose purpose The The of Imaging. Resonance

UpToDate,

VA, Referenced C Comprehensive

breast. the permission permission

sta for for disease. Cancer Comprehensive

without without NCCN NCCN asymptomatic

version version version American

findings imaging

The The The Cancer Cancer Breast Breast with with for

Cancer Comprehensive the the I

without without without breast

1303. breast Br

NCCN NCCN NCCN

Cancer Cancer

from permission from permission Guidelines™ Guidelines™

. . 6/2017 the the NCCN NCCN (MN): Bloomington east

of of of

with Eur Cancer Cancer

from from 2.2017 2.2017

of College

NCCN the NCCN the NCCN the

express express

in www.eviCore.com the the the

J J cancer:

from permission Guidelines™ Guidelines™ Guidelines™

with women

wo Guidelines, Guidelines, ancer Network Network NCCN the NCCN the ancer Radiol express express express Page 24of26

with 2014 2014

written written

ACR

and and initial 2.2017

Network .

Jan

Journal

the the

V1.0 BI

go go

Expert Radiol. ultrasound, - 209(6):1404 the for Morrogh doi:10.2214/ajr.18.20157. Lee CH, Bahl Roentgenolog Discordant Imaging Europe. 2019;35(5). 13- 2019;35(5). Europe. Imaging Journal pathologic Referenced of College Expert resonance Guidelines™) National NCCN Guidelines, express Centers Women Berger Treatment. Guidelines™ https://www.cdc.gov/genomics/gtesting/file/print/fbr/BCAnaVal.pdf complete for complete for rights rights Discharge. Sanders bilateral Monticciolo Koning Lee 3.2018 from Screening. Berg of Cancer Referenced Golan NCCN NCCN Guidelines™) National anders LM. Breast MRI in the management of the discordant the of management the in MRI Breast LM. anders

Radiolo

Imaging evaluation the any any l Rights All eviCore healthcare. Society SJ,

M, NCCN the WA

reserved. reserved.

Jokich Im, MB, Mainiero Im, Guidelines Guidelines Guidelines

Breast

Network

of MA, Gadd

Trikha

at for mastectomy written 2018 Dershaw Cancer Comprehensive Cancer Comprehensive M, LM,

Amitai versio of version

gy.

Luparia

Current Nuclear

Radiology

nipple Higher

imaging

Core Journal CollegeAmerican

- 2018;174(2):463 Guidelines other and of Disease go DL, Morris with with

1410.

El and

2014(5S). y.

National for for Breast

CT. online - (1):18

permission n Newell Clinical The The Madany

without without August Y, (NCCN) Bio

from permission

discharge: Breast - Breast of

of illustrations Moy PM,

- Than

DD, Version status

Version Version A,

Medicine CD. Lehman EA, Koning Barnea of

psy the the pathologic Control

NCCN NCCN

and the and Imaging

to 27

technologies the - 2018;15(3):408 the

Bailey

L, Kopans Cancer Comprehensive

MS,

NCCN NCCN G, Practice

; 2017 the the NCCN.org.

Risk: Average . . Results.

Cancer

Cancer Moy M,

L, berman

of et Guidelines

American reconstruction: management

9, 3.201 Corporation. 3.2018, et

Y, of

dedicated

al express express Guidelines™ Guidelines™ . a Persing Moy (CDC). Prevention and Feb 2016 . 2019

468.

al. . L, of NCCN. the Menes - 209(2):465 systematic

ACR may erein Guidelines, Guidelines,

D, nipple

et Diagnostic

Radiology

Diagnostic 16. 3.2019

Guidelines L,

Journal American

Network Network

NCCN the Reserved. NCCN the

- doi:10.1007/s10549

al. 2019

al.

Genetic/Familial Genetic/Familial Breast for

Niell

College et

Appropriateness A, written written al.

Version

ACR TS.

ACR

. discharge nuclear ; . . 414 ACR

the Recommendations

Mehta

57(Supplement Breast l. of http://koninghealth.com/en/kbct/.

National 2019 National 2019 To The and and

Yield

not review 471. Cancer

. discharge nipple (NCCN) (NCCN) detection

Appropriateness u cohort retrospective

go go Appropriateness Monsees

permission permission use on the of Performance - 14(11s):s383 in

Clinical Clinical view tility

3.2018:

be reproduced

illustrations illustrations A. predictive

breast

to online to online Oncology

Radiology cancer

of Network,

Use and American

magnetic surveillance the Screening

Guidelines Guidelines

High - High MRI of

Practice Practice

imaging. B,

Breast Criteria of - meta

most Roentgenology.

screening 018-

clinically

of of

1):46S NCCN.org. NCCN.org Sickles Cancer Comprehensive Cancer Comprehensive Contrast

value

after (NCCN

. Ri

Inc.

Risk mammography, s390.

may herein may herein NCCN. the NCCN. the ; 2017 From

-9. -9. 05077

sk recent analysis

Journal

8924 MRI

Criteria Ann Criteria Cancer. ®

and

Guidelines Guidelines All

negative - - Assessment: Society Version Version Assessment: of Evaluation

core benign 52S.

any

study. EA. occult

14 ACR.the - rights Guidelines™) Oncol Surg versus

with ductography Enhanced Diagnosis.

. . . complete and

(5): ®

. form of

® Breast

AJR.

Breast

Referenced

Breast imaging: To To

not not

Roentgenology

of - 138 Breast breast

- 2019;212(5):1157 3.2019: reserved. or

galactography

imaging resonance : 2019

for in view view in breast

Accessed

be reproduced be reproduced

of mammography inconclusive breast Journal Journal American

153. Oncology Oncology

Cancer

biopsy. Diagnostic Diagnostic biopsy.

Breast

any

Breast . MRI Nipple Pain. National Cancer

2007

cancer.

Cancer the the

and

recommendations Breast Breast for

imaging

purpose

Network, Network, version MRI, The in

with

most most

College American ; of Breast

magnetic

and and Ovarian. www.eviCore.com Screening Management 14; March

J J the

. (NCCN (NCCN

NCCN

and Research Comprehensive

Cancer. Cancer permission breast

; 2017

in Page 25of26 Am recent recent 3369 . . Ovarian

of white

American in in

without 1165. women

Cancer Inc. Inc.

18,

the any any Coll

after . .

of .

in and and All All r. r. pape 2019.

NCCN

form form

V1.0

the

with of from

Breast Imaging 0 ukatrPaeBuead lftn C290(0)918- 29910 (800) SC Bluffton, Place Boulevard, 400 Buckwalter ______Breast 49. 51. 50. 48. 52. 53. 54. 55. 57. 56. 58. 59. 60. 61. 62. ©2020 http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf you . doi:10.1016/j.jacr.2018.09.013 Pregnant doi:10.1007/s10911-006-9017-1. Imaging theBreast.JournalofMammaryGlandBiologyandNeoplasia.2006;11(2):103-111. Pa (MRI) o Quality Evaluation.Radiology.2001;221(3):657-667.doi:10.1148/radiol.2213010334. doi:10.1148/radiol.101761. annurev.bioeng.9.060906.151924. 2010;257(1):246-253. doi:10.1148/radiol.10100570. Clinical Experience.Radiology2008;246:725-733. Experience. Radiology.2010;256(3):714-723.doi:10.1148/radiol.10092311. Radiology. 2016;85(1):297-303.doi:10.1016/j.ejrad.2015.09.020. benign micro-calcificationsbydedicatedbreastcomputedtomography.EuropeanJournalof British JournalofRadiology.2019;92(1097):20181034.doi:10.1259/bjr.20181034. contrast enhancedbreastCTcomparedtodigitaltomosynthesisandmammography.The s12609-016-0227-2. Technique oftheFuture.CurrentBreastCancerReports.2016;8(4):242-247.doi:10.1007/ cdrh_docs/pdf13/P130022b.pdf. AccessedNovember5,2020. Diflorio-A Boone JM,KwanALC,YangK,BurkettGW,LindforsKK,NelsonTR.ComputedTomographyfor Children’s ACR PracticePa Boone JM,NelsonTR,LindforsKK,SeibertJA.DedicatedBreastCT:RadiationDoseandImage Diekmann F.Contrast-enhancedDedicatedBreastCT.Radiology.2011;258(2):650-650. Glick SJ.BreastCT.AnnualReviewofBiomedicalEngineering.2007;9(1):501-526.doi:10.1146/ Hendrick RE.RadiationDosesandCancerRisksfromBreastImagingStudies.Radiology. Lindfors KK,BooneJM,NelsonTR,YangK,KwanALC,MillerDF.DedicatedBreastCT:Initial The FutureofBreastImagingisHere.KoningCorporation.http://koninghealth.com/en/. Prionas ND,LindforsKK,RayS,etal.Contrast-enhancedDedicatedBreastCT:InitialClinical Aminololama-Shakeri S,AbbeyCK,GaziP,etal.Differentiationofductalcarcinomain-situfrom Aminololama-Shakeri S,AbbeyCK,LópezJE,etal.Conspicuityofsuspiciousbreastlesionson Aminololama-Shakeri S,HargreavesJB,BooneJM,LindforsKK.DedicatedBreastCT:Screening SUMMARY OFSAFETYANDEFFECTIVENESSDATA(SSED).https://www.accessdata.fda.gov/

rameters/mr-c Imaging l Rights All eviCore healthcare. version5.0.Monrovia,CA:hildren’sOncologyGroup;pg90.ctober2018. ng adultcancers, f theBr andLactatingWomen.JournaloftheAmericanCollegeRadiology.2018;15(11). lexander RM,Slanetz Oncology Guidelines east. Revised2018.(Resolution34).https://www.acr.org/-/ ontrast rameter forthePe Group.Long-t

-b reast.pdf. PJ,MoyL,etal.ACRppropriatenessCriteria Reserved. erm rformance ofCo followupguidelinesforsurvivorsofc ntrast-E nhanced Ma 8924 gnetic Re media/ACR/Files/Practice- hildhood, adolescentand ® .

Breast Imagingof sonance Im www.eviCore.com Page 26of aging V1.0

Breast Imaging